Clinical science
Prosthetic replacement of the ocular surface ecosystem: impact at 5 years Joshua S Agranat,1,2 Nicole R Kitos,3 Deborah S Jacobs1 1
Boston Foundation for Sight, Needham, Massachusetts, USA 2 Boston University School of Medicine, Boston, Massachusetts, USA 3 Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA Correspondence to Joshua S Agranat, Boston Foundation for Sight, 464 Hillside Avenue # 205, Needham, MA 02494, USA; [email protected] Preliminary analyses of data reported in this manuscript were presented at the American Academy of Ophthalmology Annual Meeting, Chicago, October 2014, ARVO 2014 Annual Meeting, Orlando, May 2014 and Cornea Society/EBAA, New Orleans, November 2013. Received 13 July 2015 Revised 23 September 2015 Accepted 8 November 2015 Published Online First 7 December 2015
ABSTRACT Background/aims To determine the impact of prosthetic replacement of the ocular surface ecosystem (PROSE) treatment at 5 years. Methods Retrospective review of clinical, manufacturing and quality databases at the Boston Foundation for Sight. Results 121 patients who completed treatment and had 5-year follow-up data were identified from a cohort of patients (n=199) seen in consultation for PROSE treatment from January 2008 to June 2008. Mean age was 52 years, M:F=56:65. The primary indication for treatment was ocular surface disease (OSD) in 64 patients and distorted corneal surface in 57 patients. At 5 years, continued device wear was confirmed in 89/121 (73.6%) patients. Discontinuation of wear was confirmed in 32/121 (26.4%). There was an increased likelihood of continued device wear at 5 years in patients with distorted cornea (84%) compared with those with OSD (64%), ( p=0.0121, χ2). National Eye Institute Visual Function Questionnaire (NEI VFQ-25) composite score increased for patients wearing PROSE devices at 6 months (Δ=+23 points, mean=82, p
Prosthetic replacement of the ocular surface ecosystem: impact at 5 years Joshua S Agranat,1,2 Nicole R Kitos,3 Deborah S Jacobs1 1
Boston Foundation for Sight, Needham, Massachusetts, USA 2 Boston University School of Medicine, Boston, Massachusetts, USA 3 Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA Correspondence to Joshua S Agranat, Boston Foundation for Sight, 464 Hillside Avenue # 205, Needham, MA 02494, USA; [email protected] Preliminary analyses of data reported in this manuscript were presented at the American Academy of Ophthalmology Annual Meeting, Chicago, October 2014, ARVO 2014 Annual Meeting, Orlando, May 2014 and Cornea Society/EBAA, New Orleans, November 2013. Received 13 July 2015 Revised 23 September 2015 Accepted 8 November 2015 Published Online First 7 December 2015
ABSTRACT Background/aims To determine the impact of prosthetic replacement of the ocular surface ecosystem (PROSE) treatment at 5 years. Methods Retrospective review of clinical, manufacturing and quality databases at the Boston Foundation for Sight. Results 121 patients who completed treatment and had 5-year follow-up data were identified from a cohort of patients (n=199) seen in consultation for PROSE treatment from January 2008 to June 2008. Mean age was 52 years, M:F=56:65. The primary indication for treatment was ocular surface disease (OSD) in 64 patients and distorted corneal surface in 57 patients. At 5 years, continued device wear was confirmed in 89/121 (73.6%) patients. Discontinuation of wear was confirmed in 32/121 (26.4%). There was an increased likelihood of continued device wear at 5 years in patients with distorted cornea (84%) compared with those with OSD (64%), ( p=0.0121, χ2). National Eye Institute Visual Function Questionnaire (NEI VFQ-25) composite score increased for patients wearing PROSE devices at 6 months (Δ=+23 points, mean=82, p
